Researchers Identified New Lung Cancer Resistance Mechanism
A study revealed that the BMF protein regulates how certain lung cancer cells survive targeted drug therapies.
Updated on Oct. 5, 2026 in Cancer
Scientists have identified the BMF protein as a critical regulator of drug-tolerant persister cells in ALK-positive lung cancer. This mechanism helps explain how tumor cells resist ALK-TKI treatments, leading to potential new therapeutic targets.
Why it matters
Understanding how cancer cells develop resistance to treatment is vital for improving patient outcomes. By identifying BMF as a key player in this survival process, researchers have uncovered potential new ways to eliminate these stubborn cells.
Researchers used genome-wide CRISPR-Cas9 knockout screening to analyze patient-derived ALK-positive NSCLC cells. The study found that BMF expression increases within 24 hours of initiating ALK-TKI treatment.
The players
Nature
Nature is a leading multidisciplinary scientific journal that publishes high-impact peer-reviewed research.
The details
The research demonstrated that the loss of BMF promotes the formation of drug-tolerant persister cells, contributing to therapy resistance in ALK and ROS1-positive lung cancers. Targeting the MCL-1 or FOXO1 proteins may provide a strategy to induce apoptosis and eliminate these resistant cell populations.
Timeline
BMF expression levels were observed to rise within 24 hours of starting ALK-TKI treatment.
The Big Picture
This discovery updates the established understanding of ALK-positive non-small cell lung cancer targeted therapy research by pinpointing BMF as a central regulator of drug resistance.
This research provides a scientific foundation for developing future therapies that could prevent cancer cells from developing resistance to current drugs. These findings may eventually expand treatment options for patients whose cancers currently stop responding to standard therapies.
The takeaway
Researchers have discovered that targeting the MCL-1 or FOXO1 proteins could be a viable strategy to overcome drug resistance in certain lung cancers. These insights represent a critical step toward developing more effective combination treatments for patients.
Further reading
For more information on the latest advancements in oncology, visit the Cancer section.
More information
View the complete peer-reviewed research article for detailed study methodology.
